NASDAQ:REPL

Replimune Group Stock Forecast, Price & News

$30.50
+0.16 (+0.53 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$30.13
Now: $30.50
$31.79
50-Day Range
$29.35
MA: $32.98
$36.30
52-Week Range
$10.62
Now: $30.50
$54.85
Volume259,808 shs
Average Volume382,863 shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.63
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Replimune Group logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REPL
CUSIPN/A
CIKN/A
Phone781-222-9600
Employees122
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.01 per share

Profitability

Net Income$-52,630,000.00

Miscellaneous

Market Cap$1.42 billion
Next Earnings Date6/2/2021 (Estimated)
OptionableNot Optionable

Headlines

Replimune Group (NASDAQ:REPL) Stock Price Down 8.3%
March 29, 2021 |  americanbankingnews.com
Replimune Group (NASDAQ:REPL) Shares Up 5.3%
March 25, 2021 |  americanbankingnews.com
Is REPL A Good Stock To Buy Now?
December 13, 2020 |  finance.yahoo.com
Replimune to Participate at the SVB Leerink Oncology 1x1 Day
November 12, 2020 |  finance.yahoo.com
Replimune Group EPS misses by $0.02
November 5, 2020 |  seekingalpha.com
See More Headlines

MarketRank

Overall MarketRank

1.51 out of 5 stars

Medical Sector

495th out of 2,019 stocks

Biological Products, Except Diagnostic Industry

73rd out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$30.50
+0.16 (+0.53 %)
(As of 04/14/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive REPL News and Ratings via Email

Sign-up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Replimune Group (NASDAQ:REPL) Frequently Asked Questions

Is Replimune Group a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Replimune Group stock.
View analyst ratings for Replimune Group
or view top-rated stocks.

What stocks does MarketBeat like better than Replimune Group?

Wall Street analysts have given Replimune Group a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Replimune Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Replimune Group's next earnings date?

Replimune Group is scheduled to release its next quarterly earnings announcement on Wednesday, June 2nd 2021.
View our earnings forecast for Replimune Group
.

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) announced its earnings results on Thursday, February, 4th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by $0.03.
View Replimune Group's earnings history
.

How has Replimune Group's stock price been impacted by Coronavirus (COVID-19)?

Replimune Group's stock was trading at $11.93 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, REPL stock has increased by 155.7% and is now trading at $30.50.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for REPL?

9 Wall Street analysts have issued 1 year target prices for Replimune Group's shares. Their forecasts range from $48.00 to $67.00. On average, they anticipate Replimune Group's stock price to reach $56.00 in the next year. This suggests a possible upside of 83.6% from the stock's current price.
View analysts' price targets for Replimune Group
or view top-rated stocks among Wall Street analysts.

Who are Replimune Group's key executives?

Replimune Group's management team includes the following people:
  • Mr. Philip Astley-Sparke, CEO & Director (Age 50, Pay $613.95k)
  • Dr. Robert Coffin, Founder, Pres, Chief R&D Officer and Director (Age 56, Pay $725.79k)
  • Ms. Jean M. Franchi, Principal Accounting Officer, CFO, Treasurer, Sec. & Compliance Officer (Age 55, Pay $470.87k)
  • Dr. Pamela Esposito Ph.D., Chief Bus. Officer (Age 47, Pay $464.63k)
  • Dr. Colin Love, Chief Operating Officer (Age 63)
  • Dr. Andrea Pirzkall M.D., Chief Medical Officer (Age 51)

Who are some of Replimune Group's key competitors?

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), (BTUUQ) (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?

(REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

How do I buy shares of Replimune Group?

Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $30.50.

How much money does Replimune Group make?

Replimune Group has a market capitalization of $1.42 billion. The company earns $-52,630,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis.

How many employees does Replimune Group have?

Replimune Group employs 122 workers across the globe.

What is Replimune Group's official website?

The official website for Replimune Group is www.replimune.com.

Where are Replimune Group's headquarters?

Replimune Group is headquartered at 500 Unicorn Park, WOBURN MA, 01801.

How can I contact Replimune Group?

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at 781-222-9600 or via email at [email protected]


This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.